Secondary hemophagocytic syndrome after autologous hematopoietic cell transplant and immune therapy for neuroblastoma.
Pediatr Blood Cancer
; 66(11): e27964, 2019 11.
Article
en En
| MEDLINE
| ID: mdl-31407508
ABSTRACT
Secondary hemophagocytic syndrome (HPS) has been described after autologous hematopoietic cell transplant (AutoHCT). We report two cases of secondary HPS after novel consolidation therapy for high-risk neuroblastoma as part of an institutional phase 2 trial incorporating immunotherapy into a "standard" AutoHCT regimen. Both patients developed liver dysfunction beyond expected course of hepatic veno-occlusive disease, coagulopathy, hyperferritinemia, and when evaluated, elevated soluble interleukin-2 receptor and hemophagocytosis. These cases highlight the need for clinicians to have a high index of suspicion for immune-related complications in patients receiving immune therapies.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Células Asesinas Naturales
/
Inmunoterapia Adoptiva
/
Fallo Hepático
/
Síndrome de Respuesta Inflamatoria Sistémica
/
Trasplante de Células Madre de Sangre Periférica
/
Linfohistiocitosis Hemofagocítica
/
Antineoplásicos Inmunológicos
/
Inmunoterapia
/
Neuroblastoma
Tipo de estudio:
Etiology_studies
Límite:
Child, preschool
/
Humans
/
Infant
/
Male
Idioma:
En
Revista:
Pediatr Blood Cancer
Asunto de la revista:
HEMATOLOGIA
/
NEOPLASIAS
/
PEDIATRIA
Año:
2019
Tipo del documento:
Article